Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement

Immunovant, Inc.

2025-Q3 EPS reported -$2.10 vs consensus -$0.73 ▼ miss (-187.1%)

Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.
Pro forma cash ~$825M after $450M private placement closed Jan 15, 2025.
Batoclimab MG pivotal and CIDP period 1 results expected by March 31, 2025.
IMVT-1402: 6 INDs cleared; pivotal GD and D2T RA studies enrolling with autoinjector.
Batoclimab GD additional data (6-month remission) summer 2025; TED top-line H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.